Latest Period
Q4 2025
Security Snapshot
BRIGHT MINDS BIOSCIENCES INC. - Common Shares (DRUG) Institutional Ownership
CUSIP: 10919W405
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
74
Shares (Excl. Options)
6,590,203
Price
$78.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Shares
- Symbol
- DRUG on Nasdaq
- Shares outstanding
- 9,783,728
- Price per share
- $83.55
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 6,590,203
- Total reported value
- $514,917,301
- % of total 13F portfolios
- 0%
- Share change
- +528,534
- Value change
- +$43,333,109
- Number of holders
- 74
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Shares is tracked under CUSIP 10919W405.
- 74 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 74 to 9 between Q4 2025 and Q1 2026.
- Reported value moved from $514,917,301 to $1,916,704.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 74 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 10919W405?
CUSIP 10919W405 identifies DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 10919W405:
Significant Owners of BRIGHT MINDS BIOSCIENCES INC. - Common Shares (DRUG) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 15% | -8.8% | $103,357,513 | +$924,052 | 1,155,995 | +0.9% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| Cormorant Asset Management, LP | 9.7% | -11% | $69,321,500 | -$7,977,883 | 950,000 | -10% | Cormorant Asset Management, LP | 28 Apr 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 6.4% | $27,550,801 | 454,184 | Vivo Opportunity Fund Holdings, L.P. | 30 Sep 2025 | |||
| PERCEPTIVE ADVISORS LLC | 4.6% | -28% | $40,171,019 | +$414,952 | 449,290 | +1% | Perceptive Advisors LLC | 31 Dec 2025 |
| Adage Capital Management, L.P. | 5.6% | $24,005,770 | 395,743 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 2.9% | $6,376,530 | 206,427 | RA Capital Management, L.P. | 31 Mar 2025 | |||
| Sio Capital Management, LLC | 2.7% | -65% | $11,571,744 | -$19,506,679 | 190,764 | -63% | Sio Capital Management, LLC | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 3% | $4,175,988 | 135,189 | Point72 Asset Management, L.P. | 31 Dec 2024 | |||
| Commodore Capital LP | 0.3% | -99% | $1,685,468 | -$43,019,532 | 18,851 | -96% | Commodore Capital LP | 31 Dec 2025 |
As of 31 Dec 2025, 74 institutional investors reported holding 6,590,203 shares of BRIGHT MINDS BIOSCIENCES INC. - Common Shares (DRUG). This represents 67% of the company’s total 9,783,728 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BRIGHT MINDS BIOSCIENCES INC. - Common Shares (DRUG) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | 1,155,995 | +0.9% | 0.04% | $90,832,307 |
| Cormorant Asset Management, LP | 11% | 1,059,331 | 0% | 4.7% | $82,670,191 |
| Vivo Capital, LLC | 5.1% | 501,617 | 0% | 2.5% | $39,146,191 |
| PERCEPTIVE ADVISORS LLC | 4.6% | 449,290 | 0% | 0.64% | $35,062,592 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4% | 395,743 | 0% | 0.05% | $30,883,784 |
| BlackRock, Inc. | 4% | 394,043 | +68% | 0% | $30,751,116 |
| BRAIDWELL LP | 3.3% | 324,358 | +6.8% | 0.81% | $25,312,898 |
| Driehaus Capital Management LLC | 2.8% | 269,641 | 0.14% | $21,042,784 | |
| MPM BIOIMPACT LLC | 2.4% | 230,147 | 2.1% | $17,960,672 | |
| Balyasny Asset Management L.P. | 2.3% | 225,412 | +21% | 0.03% | $17,591,152 |
| MILLENNIUM MANAGEMENT LLC | 2% | 194,437 | +154% | 0.01% | $15,173,863 |
| Ikarian Capital, LLC | 1.6% | 159,421 | +933% | 1.6% | $12,441,215 |
| MORGAN STANLEY | 1.4% | 132,122 | -31% | 0% | $10,310,878 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.1% | 103,013 | 0.13% | $8,039,135 | |
| STEMPOINT CAPITAL LP | 0.99% | 97,340 | 1.3% | $7,596,414 | |
| ACUTA CAPITAL PARTNERS, LLC | 0.86% | 84,477 | -0.47% | 4.5% | $6,592,585 |
| Sio Capital Management, LLC | 0.84% | 81,883 | -57% | 1.1% | $6,390,149 |
| STATE STREET CORP | 0.79% | 77,278 | +13% | 0% | $6,030,775 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.65% | 63,546 | +9.8% | 0% | $4,959,129 |
| SEVEN GRAND MANAGERS, LLC | 0.51% | 50,000 | 0.3% | $3,902,000 | |
| VANGUARD GROUP INC | 0.5% | 48,576 | +7.7% | 0% | $3,790,871 |
| GOLDMAN SACHS GROUP INC | 0.5% | 48,547 | 0% | $3,788,608 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.49% | 47,490 | +69% | 0.1% | $3,706,120 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.48% | 47,278 | -12% | 2% | $3,689,575 |
| Artia Global Partners LP | 0.34% | 33,407 | 0.42% | $2,607,082 |
Institutional Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Shares (DRUG) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,267 | $1,916,704 | +$573,128 | $72.97 | 9 |
| 2025 Q4 | 6,590,203 | $514,917,301 | +$43,333,109 | $78.04 | 74 |
| 2025 Q3 | 6,040,789 | $366,118,700 | +$48,861,748 | $60.66 | 63 |
| 2025 Q2 | 5,234,387 | $136,973,710 | -$2,453,899 | $26.11 | 46 |
| 2025 Q1 | 5,217,399 | $188,361,504 | +$11,625,261 | $36.07 | 34 |
| 2024 Q4 | 4,897,032 | $176,406,965 | +$167,324,812 | $36.02 | 31 |
| 2024 Q3 | 191,547 | $229,810 | -$6,160 | $1.17 | 6 |
| 2024 Q2 | 197,030 | $207,191 | -$19,280 | $1.05 | 5 |
| 2024 Q1 | 213,375 | $255,563 | -$27,190 | $1.20 | 7 |
| 2023 Q4 | 228,082 | $329,806 | +$48,212 | $1.43 | 7 |
| 2023 Q3 | 194,505 | $309,171 | +$309,171 | $1.60 | 5 |